Animal models of α -synucleinopathy for Parkinson disease drug development

Nature Reviews Neuroscience 18, 515 (2017). doi:10.1038/nrn.2017.75 Authors: James B. Koprich, Lorraine V. Kalia & Jonathan M. Brotchie A major challenge in Parkinson disease (PD) will be to turn an emerging and expanding pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets need in vivo validation, and candidate therapeutics require appropriate preclinical platforms on which to define potential efficacy and target
Source: Nature Reviews Neuroscience - Category: Neuroscience Authors: Tags: Review Source Type: research